Ignite Creation Date:
2024-05-05 @ 12:02 PM
Last Modification Date:
2024-10-26 @ 9:19 AM
Study NCT ID:
NCT00219115
Status:
COMPLETED
Last Update Posted:
2017-02-07
First Post:
2005-09-12
Brief Title:
A Clinical Study to Compare Combination of Aliskiren HCTZ to Irbesartan HCTZ or Amlodipine HCTZ or HCTZ Alone in Obese Hypertensive Not Responsive to HCTZ 25 mg
Sponsor:
Novartis
Organization:
Novartis
Study Overview
Official Title:
A 12-week Randomized Double-blind Parallel Group Study to Evaluate the Efficacy and Safety of the Combination Aliskiren With HCTZ Compared to Irbesartan or Amlodipine With HCTZ or HCTZ Alone in Hypertensive Patients With BMI 30 kgm2 Not Adequately Responsive to HCTZ 25 mg
Status:
COMPLETED
Status Verified Date:
2017-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To evaluate the blood pressure lowering effects of the combination of aliskiren 300 mg and HCTZ 25 mg in obese patients with essential hypertension inadequately treated with HCTZ 25 mg compared to irbesartan or amlodipine with HCTZ or HCTZ alone
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None